Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study to assess the efficacy and safety of front-line combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNα2b) therapy in patients newly diagnosed with chronic phase chronic myeloid leukaemia (CP-CML)

Trial Profile

A phase II study to assess the efficacy and safety of front-line combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNα2b) therapy in patients newly diagnosed with chronic phase chronic myeloid leukaemia (CP-CML)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Peginterferon alfa-2b
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms DASA-PEGIFN
  • Most Recent Events

    • 21 Jun 2020 Status changed from recruiting to completed, according to results presented at the 25th Congress of the European Haematology Association
    • 21 Jun 2020 Results of 48 months follow-up presented at the 25th Congress of the European Haematology Association
    • 08 Dec 2015 Preliminary results (n=81) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top